CCL19 and glioblastoma: To apply the therapeutic efficacy of 7 × 19 CAR-T to EGFRvIII-positive glioblastoma, a second-generation CAR construct containing anti–EGFRvIII scFv, hinge and transmembrane region, 4-1BB, and CD3ζ signaling motifs, together with coexpression of IL7 and CCL19 sequences was designed (Supplementary Fig. S1A).